Uganda is on the verge of making a major breakthrough in the fight against HIV. The Uganda AIDS Commission has announced exciting news research has confirmed that Lenacapavir, a new drug used for pre-exposure prophylaxis (PrEP), offers 100% protection against HIV for people who are HIV negative. The drug is given as an injection once every six months, making it a highly convenient and effective option for HIV prevention.
This groundbreaking research was carried out with the help of Ugandan scientists, showing the country’s strong role in global health innovation. Lenacapavir has already been approved by the United States Food and Drug Administration (FDA), and Uganda is now preparing to bring this life-changing drug to its people.
Before Lenacapavir can be used in Uganda, several important steps must be taken. The National Drug Authority will first evaluate and license the drug to make sure it is safe and suitable for use locally. The Ministry of Health will then update its national HIV prevention guidelines to include this new method. Healthcare workers will also receive training to ensure they can properly prescribe and monitor the use of Lenacapavir.
Additionally, the government plans to add Lenacapavir to Uganda’s essential drugs list, making it more accessible to those who need it most. New tools and systems will also be put in place to keep track of how the drug is being used and to ensure proper follow-up for people who receive the injection.
Once these steps are completed, Lenacapavir will become part of Uganda’s national HIV prevention program. This will provide more options for people who are at high risk of getting HIV, helping to reduce new infections and move the country closer to ending AIDS as a public health threat by 2030.
In the meantime, the current oral PrEP will continue to be offered in health facilities. Another injectable drug, Cabotegravir which is given every two months has already been included in the country’s guidelines, and efforts to make it available in Uganda are progressing well.
Uganda remains dedicated to using science, innovation, and collaboration to protect its people and defeat HIV/AIDS once and for all. The arrival of Lenacapavir marks a new chapter of hope and progress in this important journey.
